Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
UAN: 0430-0000-19-106-H01-P Credits: 2.0 hours (0.20 ceu) Type of Activity: Knowledge TARGET AUDIENCE: This accredited activity is targeted to pharmacists
Eli Lilly As of Q2 2025, Eli Lilly holds approximately 57% of the GLP-1 market, overtaking Novo Nordisk earlier this year
People with growth hormone deficiency typically have lower muscle mass
Why you should trust us I have been writing articles about skin care and beauty for more than 25 years
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently unapproved by the MHRA, EMA, or FDA for routine clinical use
Tirzepatide builds on this foundation by simultaneously activating both GLP-1 and GIP receptors, potentially offering greater weight reduction for patients who plateau or seek enhanced results
